Mark N. Brooks

Mark N. Brooks

Auto-generated profile, based on publicly available information

Mark N. Brooks

The Institute of Cancer Research, London, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2018 in Nature Genetics
Verified
Journal Article
Open access
PDF file
FSFredrick Schumacher
Fredrick Schumacher
AOAli Amin Al Olama
Ali Amin Al Olama
SBSonja I. Berndt
Sonja I. Berndt
SBSara Benlloch
Sara Benlloch
MAMahbubl Ahmed
Mahbubl Ahmed
C(Cancer Of The Prostate In Sweden (Caps)
Cancer Of The Prostate In Sweden (Caps)
Genome-wide association studies (GWAS) and fine-mapping efforts to date have identified more than 100 prostate cancer (PrCa)-susceptibility loci. We meta-analyzed genotype data from a custom high-density array of 46,939 PrCa cases and 27,910 controls of European ancestry with previously genotyped data of 32,255 PrCa cases and 33,202 controls of European ancestry. Our analysis identified 62 novel loci associated (P < 5.0 × 10−8) with PrCa and one locus significantly associated with early-onset PrCa (≤55 years). Our findings include missense variants rs1800057 (odds ratio (OR) = 1.16; P = 8.2 × 10−9; G>C, p.Pro1054Arg) in ATM and rs2066827 (OR = 1.06; P = 2.3 × 10−9; T>G, p.Val109Gly) in CDKN1B. The combination of all loci captured 28.4% of the PrCa familial relative risk, and a polygenic risk score conferred an elevated PrCa risk for men in the ninetieth to ninety-ninth percentiles (relative risk = 2.69; 95% confidence interval (CI): 2.55–2.82) and first percentile (relative risk = 5.71; 95% CI: 5.04–6.48) risk stratum compared with the population average. These findings improve risk prediction, enhance fine-mapping, and provide insight into the underlying biology of PrCa1.

2 April 2015 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
NMNasim Mavaddat
Nasim Mavaddat
PPPaul D. P. Pharoah
Paul D. P. Pharoah
KMKyriaki Michailidou
Kyriaki Michailidou
JTJonathan Tyrer
Jonathan Tyrer
MBMark N. Brook
Mark N. Brook
MGMontserrat Garcia-Closas
Montserrat Garcia-Closas
Data for multiple common susceptibility alleles for breast cancer may be combined to identify women at different levels of breast cancer risk. Such stratification could guide preventive and screening strategies. However, empirical evidence for genetic risk stratification is lacking. We investigated the value of using 77 breast cancer-associated single nucleotide polymorphisms (SNPs) for risk stratification, in a study of 33 673 breast cancer cases and 33 381 control women of European origin. We tested all possible pair-wise multiplicative interactions and constructed a 77-SNP polygenic risk score (PRS) for breast cancer overall and by estrogen receptor (ER) status. Absolute risks of breast cancer by PRS were derived from relative risk estimates and UK incidence and mortality rates. There was no strong evidence for departure from a multiplicative model for any SNP pair. Women in the highest 1% of the PRS had a three-fold increased risk of developing breast cancer compared with women in the middle quintile (odds ratio [OR] = 3.36, 95% confidence interval [CI] = 2.95 to 3.83). The ORs for ER-positive and ER-negative disease were 3.73 (95% CI = 3.24 to 4.30) and 2.80 (95% CI = 2.26 to 3.46), respectively. Lifetime risk of breast cancer for women in the lowest and highest quintiles of the PRS were 5.2% and 16.6% for a woman without family history, and 8.6% and 24.4% for a woman with a first-degree family history of breast cancer. The PRS stratifies breast cancer risk in women both with and without a family history of breast cancer. The observed level of risk discrimination could inform targeted screening and prevention strategies. Further discrimination may be achievable through combining the PRS with lifestyle/environmental factors, although these were not considered in this report.

4 January 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DCDavid V. Conti
David V. Conti
BDBurcu F. Darst
Burcu F. Darst
LMLilit C. Moss
Lilit C. Moss
ESEdward J. Saunders
Edward J. Saunders
XSXin Sheng
Xin Sheng
CHChristopher A. Haiman
Christopher A. Haiman

27 March 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TNThe Gene Environmental Interaction And Breast Cancer (Genica) Network
The Gene Environmental Interaction And Breast Cancer (Genica) Network
MGMontserrat Garcia-Closas
Montserrat Garcia-Closas
KIkConFab Investigators
kConFab Investigators
F(Familial Breast Cancer Study (FBCS)
Familial Breast Cancer Study (FBCS)
AIAustralian Breast Cancer Tissue Bank (ABCTB) Investigators
Australian Breast Cancer Tissue Bank (ABCTB) Investigators
PKPeter Kraft
Peter Kraft

1 November 2018 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
TGThe Premenopausal Breast Cancer Collaborative Group
The Premenopausal Breast Cancer Collaborative Group
MSMinouk J. Schoemaker
Minouk J. Schoemaker
HNHazel B. Nichols
Hazel B. Nichols
LWLauren B. Wright
Lauren B. Wright
MBMark N. Brook
Mark N. Brook
ASAnthony J. Swerdlow
Anthony J. Swerdlow
Breast cancer is the most commonly diagnosed cancer among women worldwide, accounting for 25% of female cancer cases at all ages and a greater percentage among young women.1 Its complex etiology involves an unusually large range of factors, of which adiposity, often assessed as body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), is important and appears to have opposing effects at premenopausal and postmenopausal ages.

9 November 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AWAnqi Wang
Anqi Wang
JSJiayi Shen
Jiayi Shen
ARAlex A. Rodriguez
Alex A. Rodriguez
ESEdward J. Saunders
Edward J. Saunders
FCFei Chen
Fei Chen
CHChristopher A. Haiman
Christopher A. Haiman